Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00267904 · ClinicalTrials.gov registry record · Phase 1

Reference Values for Plasma Catechols

A Phase 1 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
Phase 1
Development phase
46
Enrollment target

NCT00267904 is a Phase 1 study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00267904, a Phase 1 study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target

Study Summary

Objectives: Plasma levels of catechols have distinct meanings in terms of indicating functions of endogenous catecholamine systems. This Protocol is designed to enable ongoing quality assurance of diagnostic and research assays of catechols and their metabolites and to identify possible influences of demographic and anthropometric factors, dietary constituents, and conditions of sampling on reference values. Study Populations: The study population is healthy volunteers and people who are obese or have untreated hypertension. Design: Arm venous blood is drawn via an indwelling i.v. catheter from healthy volunteers across demographic and anthropometric spectra (age, gender, skin color, ethnicity, body mass, adiposity), to obtain quality control plasma and establish reference values for plasma levels of catechols and their metabolites. Non-invasive physiological measures are obtained concurrently. Levels of catechols and their metabolites are related to results of common clinical pathology tests. Subgroups of subjects are tested more than once, to assess dietary influences (cereal with milk, coffee) and conditions of sampling (temperature at the skin). Outcome Measures: The main non-experimental outcome is an ongoing pool of quality control plasma. The main experimental outcome measures are plasma concentrations of catechols and their metabolites, non-invasive physiological measures, and results of common clinical pathology tests. Subject groups are compared with respect to the above demographic and anthropometric factors. Effects of the experimental manipulations are assessed within subjects

Interventions

  • OTHER Coffee
  • OTHER Banana
  • OTHER Olives
  • OTHER Temp. manip.

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2006-03-08
Est. Completion 2022-03-18
Phase Phase 1

What the Registry Record Tells You About NCT00267904

The ClinicalTrials.gov registry entry for NCT00267904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Coffee is the first listed.

NCT00267904 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00267904 about?

NCT00267904 is a clinical study titled "Reference Values for Plasma Catechols". Objectives: Plasma levels of catechols have distinct meanings in terms of indicating functions of endogenous catecholamine systems. This Protocol is designed to enable ongoing quality assurance of diagnostic and research assays of catechols and their metabolites and to identify possible influences o...

What is the current status of trial NCT00267904?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2006-03-08. Estimated completion is 2022-03-18.

What interventions are being tested in trial NCT00267904?

The interventions under investigation include: Coffee (OTHER), Banana (OTHER), Olives (OTHER), Temp. manip. (OTHER).

Who is sponsoring clinical trial NCT00267904?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.